Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.
Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.
复制标题
DOI：
10.1093/infdis/jis710
复制
发表时间：
2013-02
期刊：
影响因子：
--
通讯作者：
G. Raczniak;L. Bulkow;M. Bruce;C. Zanis;R. Baum;Mary M Snowball;Kathy K. Byrd;U. Sharapov;T. Henn
中科院分区：
文献类型：
--
作者：
G. Raczniak;L. Bulkow;M. Bruce;C. Zanis;R. Baum;Mary M Snowball;Kathy K. Byrd;U. Sharapov;T. Henn
疾病控制和预防中心建议所有1岁的儿童和高危成年人接种甲型肝炎病毒(HAV)疫苗。该疫苗非常有效；然而，保护期尚不清楚。我们报告了儿童免疫17年后甲型肝炎病毒抗体浓度，表明保护性抗体水平仍然存在，并在过去7年中稳定下来。
The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.